PPARs and HCV-related hepatocarcinoma: A mitochondrial point of view

PPAR Research

Volumn , Issue , 2012, Pages

  Agriesti, Francesca ^a   Tataranni, Tiziana ^a   Ruggieri, Vitalba ^a   Capitanio, Nazzareno ^b   Piccoli, Claudia ^a,b  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A OXIDASE; BEZAFIBRATE; GLUCOSE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 5B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RETINOID X RECEPTOR; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSFORMING GROWTH FACTOR BETA; VIRUS PROTEIN;

ADIPOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BIOACCUMULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA SEQUENCE; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ESOPHAGUS VARICES; FATTY ACID OXIDATION; FATTY LIVER; GENOTYPE; GLUCOSE METABOLISM; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; LIPID COMPOSITION; LIPID METABOLISM; LIPID PEROXIDATION; LIPOLYSIS; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER METABOLISM; MITOCHONDRIAL MEMBRANE; NONHUMAN; OPEN READING FRAME; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH VARICES; TUMOR SUPPRESSOR GENE; UPREGULATION; VIRUS REPLICATION;

EID: 84866172229     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/605302     Document Type: Review

References (93)

1. Ament Z., Masoodi M., Griffin J. L., Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer. Genome Medicine 2012 4 4 32 2-s2.0-84860469666 10.1186/gm331
2. Peters J. M., Cheung C., Gonzalez F. J., Peroxisome proliferator- activated receptor- α and liver cancer: where do we stand? Journal of Molecular Medicine 2005 83 10 774 785 2-s2.0-26044475136 10.1007/s00109-005- 0678-9 (Pubitemid 41407861)
3. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J. P., Staels B., Auwerx J., Laville M., Vidal H., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor- α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997 46 8 1319 1327 2-s2.0-0030747895 (Pubitemid 27315281)
4. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990 347 6294 645 650 2-s2.0-0025132245 10.1038/347645a0 (Pubitemid 20356241)
5. Lazarow P. B., De Duve C., A fatty acyl CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. Proceedings of the National Academy of Sciences of the United States of America 1976 73 6 2043 2046 2-s2.0-0342528190
6. Reddy J. K., Krishnakantha T. P., Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate. Science 1975 190 4216 787 789 2-s2.0-0016709214
7. Peters J. M., Cattley R. C., Gonzalez F. J., Role of PPAR α in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997 18 11 2029 2033 2-s2.0-0031418657 10.1093/carcin/18.11.2029 (Pubitemid 28134725)
8. Yeldandi A. V., Rao M. S., Reddy J. K., Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutation Research 2000 448 2 159 177 2-s2.0-0034678013 10.1016/S0027-5107(99)00234-1 (Pubitemid 30139452)
9. Reddy J. K., Hashimoto T., Peroxisomal β -oxidation and peroxisome proliferatoractivated receptor α: an adaptive metabolic system. Annual Review of Nutrition 2001 21 193 230 2-s2.0-0034939632 10.1146/annurev.nutr.21.1. 193 (Pubitemid 32695270)
10. Scatena R., Bottoni P., Martorana G. E., Ferrari F., De Sole P., Rossi C., Giardina B., Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. Biochemical and Biophysical Research Communications 2004 319 3 967 973 2-s2.0-2942592344 10.1016/j.bbrc.2004.05.072 (Pubitemid 38739414)
11. Fruehauf J. P., Meyskens F. L., Reactive oxygen species: a breath of life or death? Clinical Cancer Research 2007 13 3 789 794 2-s2.0-33847349283 10.1158/1078-0432.CCR-06-2082 (Pubitemid 46340350)
12. Semenza G. L., Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 2003 3 10 721 732 2-s2.0-0142166332 (Pubitemid 37328811)
13. Shi D. Y., Deng Y. R., Liu S. L., Zhang Y. D., Wei L., Redox stress regulates cell proliferation and apoptosis of human hepatoma through Akt protein phosphorylation. FEBS Letters 2003 542 1-3 60 64 2-s2.0-0038743128 10.1016/S0014-5793(03)00338-7 (Pubitemid 36555714)
14. Bayley J. P., Devilee P., The Warburg effect in 2012. Current opinion in oncology 2012 24 1 62 67 2-s2.0-84856385470
15. Bensinger S. J., Christofk H. R., New aspects of the Warburg effect in cancer cell biology. Seminars in Cell and Developmental Biology 2012 23 4 352 361 2-s2.0-84861964103 10.1016/j.semcdb.2012.02.003
16. Heiden M. G. V., Cantley L. C., Thompson C. B., Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 2009 324 5930 1029 1033 2-s2.0-66249108601 10.1126/science.1160809
17. Kroemer G., Pouyssegur J., Tumor cell metabolism: cancer's Achilles' Heel. Cancer Cell 2008 13 6 472 482 2-s2.0-44449147036 10.1016/j.ccr.2008.05.005 (Pubitemid 351766797)
18. Jones R. G., Thompson C. B., Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes and Development 2009 23 5 537 548 2-s2.0-61849135453 10.1101/gad.1756509
19. Kitamura K., Hatano E., Higashi T., Narita M., Seo S., Nakamoto Y., Yamanaka K., Nagata H., Taura K., Yasuchika K., Nitta T., Uemoto S., Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. Journal of Hepatology 2011 55 4 846 857 2-s2.0-79959420482 10.1016/j.jhep.2011.01.038
20. Amann T., Maegdefrau U., Hartmann A., Agaimy A., Marienhagen J., Weiss T. S., Stoeltzing O., Warnecke C., Schölmerich J., Oefner P. J., Kreutz M., Bosserhoff A. K., Hellerbrand C., GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. American Journal of Pathology 2009 174 4 1544 1552 2-s2.0-65349095566 10.2353/ajpath.2009.080596
21. Qu A., Shah Y. M., Matsubara T., Yang Q., Gonzalez F. J., PPAR α -dependent activation of cell cycle control and DNA repair genes in hepatic nonparenchymal cells. Toxicological Sciences 2010 118 2 404 410 2-s2.0-78549248181 10.1093/toxsci/kfq259 kfq259
22. Woods C. G., Burns A. M., Bradford B. U., Ross P. K., Kosyk O., Swenberg J. A., Cunningham M. L., Rusyn I., WY-14,643-induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase. Toxicological Sciences 2007 98 2 366 374 2-s2.0-34547830255 10.1093/toxsci/kfm104 (Pubitemid 47244809)
23. Yang Q., Ito S., Gonzalez F. J., Hepatocyte-restricted constitutive activation of PPAR α induces hepatoproliferation but not hepatocarcinogenesis. Carcinogenesis 2007 28 6 1171 1177 2-s2.0-34250168573 10.1093/carcin/bgm046 (Pubitemid 47062675)
24. Reuter S., Gupta S. C., Chaturvedi M. M., Aggarwal B. B., Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biology and Medicine 2010 49 11 1603 1616 2-s2.0-78049370987 10.1016/j.freeradbiomed.2010. 09.006
25. Hays T., Rusyn I., Burns A. M., Kennett M. J., Ward J. M., Gonzalez F. J., Peters J. M., Role of peroxisome proliferator-activated receptor- α (PPAR α) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 2005 26 1 219 227 2-s2.0-13444311098 10.1093/carcin/bgh285 (Pubitemid 40207717)
26. Roberts R. A., James N. H., Hasmall S. C., Holden P. R., Lambe K., Macdonald N., West D., Woodyatt N. J., Whitcome D., Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPAR α Toxicology Letters 2000 112-113 49 57 2-s2.0-17344379118 10.1016/S0378-4274(99) 00243-X (Pubitemid 30138104)
27. Klaunig J. E., Babich M. A., Baetcke K. P., Cook J. C., Corton J. C., David R. M., DeLuca J. G., Lai D. Y., McKee R. H., Peters J. M., Roberts R. A., Fenner-Crisp P. A., PPAR α agonist-induced rodent tumors: modes of action and human relevance. Critical Reviews in Toxicology 2003 33 6 655 780 2-s2.0-0346156024 (Pubitemid 38037444)
28. Chen H. H., Sue Y. M., Chen C. H., Hsu Y. H., Hou C. C., Cheng C. Y., Lin S. L., Tsai W. L., Chen T. W., Chen T. H., Peroxisome proliferator-activated receptor alpha plays a crucial role in l-carnitine anti-apoptosis effect in renal tubular cells. Nephrology Dialysis Transplantation 2009 24 10 3042 3049 2-s2.0-70349490367 10.1093/ndt/gfp258
29. Matsumoto K., Yu S., Jia Y., Ahmed M. R., Viswakarma N., Sarkar J., Kashireddy P. V., Rao M. S., Karpus W., Gonzalez F. J., Reddy J. K., Critical role for transcription coactivator Peroxisome Proliferator- activated Receptor (PPAR)-binding protein/TRAP220 in liver regeneration and PPAR α ligand-induced liver tumor development. Journal of Biological Chemistry 2007 282 23 17053 17060 2-s2.0-34447122582 10.1074/jbc.M701956200 (Pubitemid 47093249)
30. Shah Y. M., Morimura K., Yang Q., Tanabe T., Takagi M., Gonzalez F. J., Peroxisome proliferator-activated receptor α regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Molecular and Cellular Biology 2007 27 12 4238 4247 2-s2.0-34250163202 10.1128/MCB.00317-07 (Pubitemid 46906549)
31. Koeffer H. P., Peroxisome proliferators-activated receptor gamma and carcinomas. Clinical Cancer Research 2003 9 1 9
32. Sertznig P., Seifert M., Tilgen W., Reichrath J., Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. Journal of Cellular Physiology 2007 212 1 1 12 2-s2.0-34249948005 10.1002/jcp.20998 (Pubitemid 46876399)
33. Grommes C., Landreth G. E., Heneka M. T., Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncology 2004 5 7 419 429 2-s2.0-3042815666 10.1016/S1470-2045(04)01509-8 (Pubitemid 38878045)
34. Yu J., Qiao L., Zimmermann L., Ebert M. P. A., Zhang H., Lin W., Röcken C., Malfertheiner P., Farrell G. C., Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006 43 1 134 143 2-s2.0-33644792520 10.1002/hep.20994 (Pubitemid 43733600)
35. Hsu M. C., Huang C. C., Chang H. C., Hu T. H., Hung W. C., Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor γ ligands in vitro and in vivo. Clinical Cancer Research 2008 14 13 4045 4052 2-s2.0-48249136165 10.1158/1078-0432.CCR- 07-5040
36. Han C., Bowen W. C., Li G., Demetris A. J., Michalopoulos G. K., Wu T., Cytosolic phospholipase A2 α and peroxisome proliferator-activated receptor γ signaling pathway counteracts transforming growth factor β -mediated inhibition of primary and transformed hepatocyte growth. Hepatology 2010 52 2 644 655 2-s2.0-77955697348 10.1002/hep.23703
37. Shepard C. W., Finelli L., Alter M. J., Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005 5 9 558 567 2-s2.0-23944506014 10.1016/S1473-3099(05)70216-4 (Pubitemid 41196755)
38. Reed K. E., Rice C. M., Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Current Topics in Microbiology and Immunology 2000 242 55 84 2-s2.0-0033992516 (Pubitemid 29467521)
39. Vendemiale G., Grattagliano I., Portincasa P., Serviddio G., Palasciamo G., Altomare E., Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up. European Journal of Clinical Investigation 2001 31 1 54 63 2-s2.0-0035138099 10.1046/j.1365-2362.2001.00747.x (Pubitemid 32151122)
40. Paradis V., Kollinger M., Fabre M., Holstege A., Poynard T., Bedossa P., In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 1997 26 1 135 142 2-s2.0-0031011220 (Pubitemid 27280317)
41. Serejo F., Emerit I., Filipe P. M., Fernandes A. C., Costa M. A., Freitas J. P., Carneiro de Moura M., Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features. Canadian Journal of Gastroenterology 2003 17 11 644 650 2-s2.0-0346777284 (Pubitemid 37536844)
42. Piccoli C., Scrima R., D'Aprile A., Ripoli M., Lecce L., Boffoli D., Capitanio N., Mitochondrial dysfunction in hepatitis C virus infection. Biochimica et Biophysica Acta 2006 1757 9-10 1429 1437 2-s2.0-33748958673 10.1016/j.bbabio.2006.05.018 (Pubitemid 44442124)
43. Moradpour D., Penin F., Rice C. M., Replication of hepatitis C virus. Nature Reviews Microbiology 2007 5 6 453 463 2-s2.0-34249024924 10.1038/nrmicro1645 (Pubitemid 46780082)
44. Mottola G., Cardinali G., Ceccacci A., Trozzi C., Bartholomew L., Torrisi M. R., Pedrazzini E., Bonatti S., Migliaccio G., Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology 2002 293 1 31 43 2-s2.0-0036346236 10.1006/viro.2001.1229
45. Nomura-Takigawa Y., Nagano-Fujii M., Deng L., Kitazawa S., Ishido S., Sada K., Hotta H., Non-structural protein 4A of Hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis. Journal of General Virology 2006 87 7 1935 1945 2-s2.0-33745624260 10.1099/vir.0.81701-0 (Pubitemid 43985876)
46. Schwer B., Ren S., Pietschmann T., Kartenbeck J., Kaehlcke K., Bartenschlager R., Yen T. S. B., Ott M., Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif. Journal of Virology 2004 78 15 7958 7968 2-s2.0-3242673323 10.1128/JVI.78.15.7958-7968. 2004 (Pubitemid 38944281)
47. Korenaga M., Wang T., Li Y., Showalter L. A., Chan T., Sun J., Weinman S. A., Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. Journal of Biological Chemistry 2005 280 45 37481 37488 2-s2.0-27844604269 10.1074/jbc.M506412200 (Pubitemid 41642356)
48. Piccoli C., Scrima R., Quarato G., D'Aprile A., Ripoli M., Lecce L., Boffoli D., Moradpour D., Capitanio N., Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology 2007 46 1 58 65 2-s2.0-34547415672 10.1002/hep.21679 (Pubitemid 47171921)
49. Moriya K., Nakagawa K., Santa T., Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Miyazawa T., Ishibashi K., Horie T., Imai K., Todoroki T., Kimura S., Koike K., Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Research 2001 61 11 4365 4370 2-s2.0-0035360859 (Pubitemid 32685760)
50. Okuda M., Li K., Beard M. R., Showalter L. A., Scholle F., Lemon S. M., Weinman S. A., Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002 122 2 366 375 2-s2.0-0036165333 (Pubitemid 34116988)
51. Ott M., Robertson J. D., Gogvadze V., Zhivotovsky B., Orrenius S., Cytochrome c release from mitochondria proceeds by a two-step process. Proceedings of the National Academy of Sciences of the United States of America 2002 99 3 1259 1263 2-s2.0-0037022352 10.1073/pnas.241655498 (Pubitemid 34136480)
52. Alderton W. K., Cooper C. E., Knowles R. G., Nitric oxide synthases: structure, function and inhibition. Biochemical Journal 2001 357 3 593 615 2-s2.0-0035425503 10.1042/0264-6021:3570593 (Pubitemid 32735142)
53. Ghafourifar P., Cadenas E., Mitochondrial nitric oxide synthase. Trends in Pharmacological Sciences 2005 26 4 190 195 2-s2.0-15944382742 10.1016/j.tips.2005.02.005 (Pubitemid 40432654)
54. Brown G. C., Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. Biochimica et Biophysica Acta 2001 1504 1 46 57 2-s2.0-0035282782 10.1016/S0005-2728(00)00238-3 (Pubitemid 32179657)
55. Shiva S., Darley-Usmar V. M., Control of the nitric oxide-cytochrome C oxidase signaling pathway under pathological and physiological conditions. IUBMB Life 2003 55 10-11 585 590 2-s2.0-0345731024 10.1080/152165430310001640489 (Pubitemid 38019835)
56. Jekabsone A., Ivanoviene L., Brown G. C., Borutaite V., Nitric oxide and calcium together inactivate mitochondrial complex I and induce cytochrome c release. Journal of Molecular and Cellular Cardiology 2003 35 7 803 809 2-s2.0-0038462137 10.1016/S0022-2828(03)00137-8 (Pubitemid 36773593)
57. Brookes P. S., Yoon Y., Robotham J. L., Anders M. W., Sheu S. S., Calcium, ATP, and ROS: a mitochondrial love-hate triangle. American Journal of Physiology. Cell Physiology 2004 287 4 C817 C833 2-s2.0-4544235673 10.1152/ajpcell.00139.2004 (Pubitemid 39238305)
58. Tardif K. D., Waris G., Siddiqui A., Hepatitis C virus, ER stress, and oxidative stress. Trends in Microbiology 2005 13 4 159 163 2-s2.0-16244405250 10.1016/j.tim.2005.02.004 (Pubitemid 40463317)
59. Papa S., Skulachev V. P., Reactive oxygen species, mitochondria, apoptosis and aging. Molecular and Cellular Biochemistry 1997 174 1-2 305 319 2-s2.0-0030809576 10.1023/A:1006873518427 (Pubitemid 27404207)
60. Inoue M., Sato E. F., Nishikawa M., Park A. M., Kira Y., Imada I., Utsumi K., Mitochondrial generation of reactive oxygen species and its role in aerobic life. Current Medicinal Chemistry 2003 10 23 2495 2505 2-s2.0-0344513852 10.2174/0929867033456477 (Pubitemid 37460972)
61. Machida K., Cheng K. T. H., Lai C. K., Jeng K. S., Sung V. M. H., Lai M. M. C., Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STATS activation. Journal of Virology 2006 80 14 7199 7207 2-s2.0-33745797050 10.1128/JVI.00321-06 (Pubitemid 44025216)
62. Storz P., Reactive oxygen species in tumor progression. Frontiers in Bioscience 2005 10 2 1881 1896 2-s2.0-17244367828 (Pubitemid 40529044)
63. Cardin R., Piciocchi M., Sinigaglia A., Lavezzo E., Bortolami M., Kotsafti A., Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocelllular carcinoma. BMC Cancer 2012 12 1, article 177 10.1186/1471-2407-12-177
64. Lim J. S., Park S. H., Jang K. L., Hepatitis C virus Core protein overcomes stress-induced premature senescence by down-regulating p16 expression via DNA methylation. Cancer Letters 2012 321 2 154 161 10.1016/j.canlet.2012.01. 044
65. Tsutsumi T., Suzuki T., Moriya K., Shintani Y., Fujie H., Miyoshi H., Matsuura Y., Koike K., Miyamura T., Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 2003 38 4 820 828 2-s2.0-0141866947 10.1053/jhep.2003.50399 (Pubitemid 37221665)
66. Tsutsumi T., Suzuki T., Moriya K., Yotsuyanagi H., Shintani Y., Fujie H., Matsuura Y., Kimura S., Koike K., Miyamura T., Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 2002 304 2 415 424 2-s2.0-12244276796 10.1006/viro.2002.1702 (Pubitemid 36069179)
67. Liu J., Ding X., Tang J., Cao Y., Hu P., Zhou F., Enhancement of canonical Wnt/ β -catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS One 2011 6 11 e27496 10.1371/journal.pone.0027496
68. Jahan S., Khaliq S., Siddiqi M. H., Ijaz B., Ahmad W., Ashfaq U. A., Anti-apoptotic effect of HCV core gene of genotype 3a in Huh-7 cell line. Virology Journal 2011 8 article 522 10.1186/1743-422X-8-522
69. Ripoli M., D'Aprile A., Quarato G., Sarasin-Filipowicz M., Gouttenoire J., Scrima R., Cela O., Boffoli D., Heim M. H., Moradpour D., Capitanio N., Piccoli C., Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1 α -mediated glycolytic adaptation. Journal of Virology 2010 84 1 647 660 2-s2.0-72849136940 10.1128/JVI.00769-09
70. Watashi K., Hijikata M., Tagawa A., Doi T., Marusawa H., Shimotohno K., Modulation of retinoid signaling by a cytoplasmic viral protein via sequestration of sp110b, a potent transcriptional corepressor of retinoic acid receptor, from the nucleus. Molecular and Cellular Biology 2003 23 21 7498 7509 2-s2.0-0142123224 10.1128/MCB.23.21.7498-7509.2003 (Pubitemid 37271451)
71. Morbitzer M., Herget T., Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells. Journal of Biological Chemistry 2005 280 10 8831 8841 2-s2.0-15744376980 10.1074/jbc.M413730200 (Pubitemid 40409572)
72. Fujita N., Kaito M., Kai M., Sugimoto R., Tanaka H., Horiike S., Konishi M., Iwasa M., Watanabe S., Adachi Y., Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. Journal of Viral Hepatitis 2006 13 7 441 448 2-s2.0-33745193547 10.1111/j.1365-2893.2005.00718.x
73. Chang K. O., George D. W., Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. Journal of Virology 2007 81 18 9633 9640 2-s2.0-35348837827 10.1128/JVI.00795-07 (Pubitemid 350067669)
74. Pazienza V., Vinciguerra M., Andriulli A., Mangia A., Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR- γ in Huh-7 cells. Journal of General Virology 2010 91 7 1678 1686 2-s2.0-77954168704 10.1099/vir.0.020644-0
75. Dharancy S., Malapel M., Perlemuter G., Roskams T., Cheng Y., Dubuquoy L., Podevin P., Conti F., Canva V., Philippe D., Gambiez L., Mathurin P., Paris J. C., Schoonjans K., Calmus Y., Pol S., Auwerx J., Desreumaux P., Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005 128 2 334 342 2-s2.0-14944374003 10.1053/j.gastro.2004.11.016 (Pubitemid 40431087)
76. Yasui K., Harano Y., Mitsuyoshi H., Tsuji K., Endo M., Nakajima T., Minami M., Itoh Y., Zen Y., Nakanuma Y., Yoshikawa T., Okanoue T., Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. Journal of Gastroenterology 2010 45 1 95 104 2-s2.0-77949272197 10.1007/s00535-009-0133-8
77. Dharancy S., Lemoine M., Mathurin P., Serfaty L., Dubuquoy L., Peroxisome proliferator-activated receptors in HCV-related infection. PPAR Research 2009 2009 5 2-s2.0-65349175993 10.1155/2009/357204 357204
78. Li Z. H., Tang Q. B., Wang J., Zhou L., Huang W. L., Liu R. Y., Chen R. F., Hepatitis C virus core protein induces malignant transformation of biliary epithelial cells by activating nuclear factor- κ B pathway. Journal of Gastroenterology and Hepatology 2010 25 7 1315 1320 2-s2.0-77953967458 10.1111/j.1440-1746.2009.06201.x
79. Tanaka N., Moriya K., Kiyosawa K., Koike K., Gonzalez F. J., Aoyama T., PPAR α activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. Journal of Clinical Investigation 2008 118 2 683 694 2-s2.0-38849184816 10.1172/JCI33594 (Pubitemid 351206557)
80. Tanaka N., Moriya K., Kiyosawa K., Koike K., Aoyama T., Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor α in transgenic mice: implications for HCV-associated hepatocarcinogenesis. International Journal of Cancer 2008 122 1 124 131 2-s2.0-36749083957 10.1002/ijc.23056 (Pubitemid 350209986)
81. Koike K., Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. Journal of Gastroenterology 2009 44 19 82 88 2-s2.0-58849166220 10.1007/s00535-008-2276-4
82. Rakic B., Sagan S. M., Noestheden M., Bélanger S., Nan X., Evans C. L., Xie X. S., Pezacki J. P., Peroxisome proliferator-activated receptor α antagonism inhibits hepatitis C virus replication. Chemistry and Biology 2006 13 1 23 30 2-s2.0-30744432858 10.1016/j.chembiol.2005.10.006 (Pubitemid 43099921)
83. Nishimura-Sakurai Y., Sakamoto N., Mogushi K., Nagaie S., Nakagawa M., Itsui Y., Tasaka-Fujita M., Onuki-Karakama Y., Suda G., Mishima K., Yamamoto M., Ueyama M., Funaoka Y., Watanabe T., Azuma S., Sekine-Osajima Y., Kakinuma S., Tsuchiya K., Enomoto N., Tanaka H., Watanabe M., Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells. Journal of Gastroenterology 2010 45 5 523 536 2-s2.0-77953323499 10.1007/s00535-009-0162-3
84. Fujita N., Kaito M., Tanaka H., Horiike S., Adachi Y., Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C. American Journal of Gastroenterology 2004 99 11 2280 2-s2.0-19644401237 10.1111/j.1572-0241.2004.406953.x (Pubitemid 39524721)
85. Kapadia S. B., Chisari F. V., Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proceedings of the National Academy of Sciences of the United States of America 2005 102 7 2561 2566 2-s2.0-14044265120 10.1073/pnas.0409834102 (Pubitemid 40279416)
86. Piccoli C., Quarato G., Ripoli M., D'Aprile A., Scrima R., Cela O., Boffoli D., Moradpour D., Capitanio N., HCV infection induces mitochondrial bioenergetic unbalance: causes and effects. Biochimica et Biophysica Acta 2009 1787 5 539 546 2-s2.0-67349286520 10.1016/j.bbabio.2008.11.008
87. Miyanari Y., Atsuzawa K., Usuda N., Watashi K., Hishiki T., Zayas M., Bartenschlager R., Wakita T., Hijikata M., Shimotohno K., The lipid droplet is an important organelle for hepatitis C virus production. Nature Cell Biology 2007 9 9 1089 1097 2-s2.0-34548316984 10.1038/ncb1631 (Pubitemid 47338147)
88. Boulant S., Douglas M. W., Moody L., Budkowska A., Targett-Adams P., McLauchlan J., Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic 2008 9 8 1268 1282 2-s2.0-47649114826 10.1111/j.1600-0854.2008.00767.x (Pubitemid 352016286)
89. Goldwasser J., Cohen P. Y., Lin W., Kitsberg D., Balaguer P., Polyak S. J., Chung R. T., Yarmush M. L., Nahmias Y., Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. Journal of Hepatology 2011 55 963 971 2-s2.0-79960608394 10.1016/j.jhep.2011.02.011
90. Kim K. H., Hong S. P., Kim K., Park M. J., Kim K. J., Cheong J., HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPAR γ Biochemical and Biophysical Research Communications 2007 355 4 883 888 2-s2.0-33847633412 10.1016/j.bbrc.2007.02.044 (Pubitemid 46366910)
91. Kim K., Kim K. H., Ha E., Park J. Y., Sakamoto N., Cheong J., Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Letters 2009 583 17 2720 2726 2-s2.0-69249229453 10.1016/j.febslet.2009.07.034
92. Lima-Cabello E., García-Mediavilla M. V., Miquilena-Colina M. E., Vargas-Castrillón J., Lozano-Rodríguez T., Fernández- Bermejo M., Olcoz J. L., González-Gallego J., García-Monzón C., Sánchez-Campos S., Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clinical Science 2011 120 6 239 250 2-s2.0-79251639639 10.1042/CS20100387
93. Pazienza V., Clément S., Pugnale P., Conzelman S., Foti M., Mangia A., Negro F., The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007 45 5 1164 1171 2-s2.0-34248671715 10.1002/hep.21634 (Pubitemid 46775778)